Stay updated on EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial page.

Latest updates to the EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial page
- ChecktodayChange DetectedA sitewide NIH banner announces updates about the transition from “Artificial Intelligence” to “Super Intelligence” terminology. The clinical trial page still displays a 403 Forbidden error.SummaryDifference1%

- Check7 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check14 days agoChange DetectedThe site footer now lists revision v3.7.1 instead of v3.7.0, while the page continues to show a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the previous study details with an error screen. This indicates an access restriction rather than an update to the trial content.SummaryDifference21%

- Check56 days agoChange DetectedPage revision updated from v3.6.5 to v3.6.6, indicating a maintenance/patch update to the page rendering.SummaryDifference0.1%

- Check77 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, signaling an update to the site's documentation/UI. The update does not modify the study content, eligibility criteria, or how a user interacts with the page.SummaryDifference0.0%

Stay in the know with updates to EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EphB4-HSA Fusion Protein and Pembrolizumab Clinical Trial page.